{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":6,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05200988\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"Indi-Blade","nct_id":"NCT05200988","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=indi-blade-nct05200988. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Indi-Blade","arms":[{"description":"Checkpoint inhibition and chemoradiation","label":"Induction with heckpoint inhibition followed by consolidative chemoradiation","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2027-09-05","type":"ESTIMATED"},"conditions":["Urothelial Carcinoma","Bladder Cancer"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ipilimumab + nivolumab","otherNames":["Yervoy","Opdivo"],"type":"DRUG"}],"last_update":"2024-03-18","lead_sponsor":"The Netherlands Cancer Institute","official_title":"A Phase 2 Clinical Study to Assess Efficacy of Induction Ipilimumab/Nivolumab to Spare the Bladder in Urothelial Bladder Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Efficacy defined as bladder-intact event-free survival (BI-EFS)","timeFrame":"From initiation of study drug until event, defined as described above, whichever comes first. Patients without an event are censored at time of last cystoscopy/last CT scan. Assessed at primary analysis and subsequently at a minimum of 3yrs follow-up."}],"references":[{"citation":"Mellema JJ, Stockem CF, Herberts C, Cheung SK, Vis DJ, van Rhijn BWG, Mertens LS, Boellaard TN, van Montfoort ML, Balduzzi S, de Feijter JM, van der Mijn JCK, Sharma S, El Naggar AC, Boormans JL, Franckena M, Meijer RP, Noteboom JL, Schaake EE, Robbrecht DGJ, Suelmann BBM, van der Heijden MS. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2026 Apr;32(4):1241-1248. doi: 10.1038/s41591-026-04271-3. Epub 2026 Feb 27.","pmid":"41760951","type":"DERIVED"},{"citation":"Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023.","pmid":"37711193","type":"DERIVED"}],"start_date":{"date":"2022-03-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC","url":"https://clinicaltrials.gov/study/NCT05200988"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/indi-blade-nct05200988"}